An army of enterprises sought for IPO at Hong Kong, S.A.R., China in the almost first half of 2021. Not long ago, a prospectus submitted by Beijing Advaccine Biotechnology (hereinafter, "Advaccine") for listing caused a sensation, and the launch of its coronavirus DNA vaccine also drew wide attention. Not to mention this DNA vaccine, let's find out what else R&D lines of Advaccine to expect.
Advaccine is known to be an international leading platform for vaccine development and production, and an innovative biotech that is absorbed in the development and application of innovative vaccine technologies such as DNA nucleic acid vaccines, recombinant protein vaccines, and novel vaccine adjuvants. Its current in research COVID-19 DNA vaccine, new respiratory syncytial virus (RSV) pneumonia vaccine, hepatitis B therapeutic vaccine, etc., have been reported to be associated with excellent clinical and preclinical data, and appears to usher in a wide market space.
R&D pipelines
Advaccine runs a comprehensive and innovative portfolio of technology platforms, i.e., DNA vaccine platform, recombinant protein subunit vaccine platform and novel adjuvant platform, based on which, an array of high-value vaccine products in development have been developed. It currently is engaged in developing six vaccine candidates for six disease areas, including potential pioneering vaccines developed against diseases caused by SARS-CoV-2, RSV, and HBV.
Core products
COVID-19 DNA vaccine-INO-4800
INO-4800 is recognized as a candidate DNA (deoxyribonucleic acid) vaccine developed by INOVIO for the coronavirus SARS-CoV-2 that causes COVID-19 pneumonia. DNA vaccine, also known as nucleic acid vaccine or genetic vaccine, introduces a DNA sequence encoding a certain protein antigen into a host through a vector to induce the body to produce an immune response. DNA vaccines feature high clinical safety, and are easier to produce and have an edge in R&D cost and cycle compared with live attenuated vaccines and recombinant protein vaccines. These features of DNA vaccine make it one of the strategies for researchers to develop against the COVID-19.
Advaccine and INOVIO, a US vaccine manufacturer, jointly declared that they have entered into a cooperation and licensing agreement on the COVID-19 candidate DNA vaccine INO-4800 in January of this year. The agreement states that Advaccine will have the exclusive rights to develop, manufacture and commercialize INO-4800 in the Greater China region (including China, Hong Kong, S.A.R., China, Macau, S.A.R., China and Taiwan, China).
INO-4800 currently seems to be the world's first and only COVID-19 candidate DNA vaccine under clinical development, and also the first COVID-19 candidate DNA vaccine worldwide that has been put to clinical trials in China and the United States. The clinical data of the Phase 1 study of INOVIO officially published in The Lancet reported that in a study of 38 vaccinated volunteers, the INO-4800 COVID-19 vaccine candidate presented 100% safety and resistance, receptivity and immunogenicity, as well as the ability to stimulate humoral immunity and cellular immunity simultaneously. INO-4800 is undergoing Phase 3 clinical trials and Phase 2 clinical trials in the United States and China respectively, including main subjects of 18 years old and older. Phase 3 clinical trials of INO-4800 will be conducted in China in the second quarter of this year, and a marketing application will be made to NMPA as scheduled in the second half of 2021.
On top of that, INO-4800 provides many benefits, including: stability for more than one year at room temperature, storage for more than one month at 37°C, and a shelf life of five years at normal refrigeration temperature (2-8°C); no need to freeze during pharma cold chain logistics transportation or storage, meeting all the key conditions for timely distribution of COVID-19 vaccines.
2. RSV vaccine-ADV110
ADV110 is established as a vaccine candidate against respiratory syncytial virus (RSV) and the only RSV vaccine candidate designed and d...
(All Rights Reserved)